Equities

Kazia Therapeutics Ltd

KZIA:NAQ

Kazia Therapeutics Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.2301
  • Today's Change-0.012 / -5.05%
  • Shares traded508.37k
  • 1 Year change-81.74%
  • Beta2.1491
Data delayed at least 15 minutes, as of Jun 14 2024 20:59 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Kazia Therapeutics Limited is an oncology focused drug development company. The Company is engaged in the pharmaceutical research and development. Its lead program includes Paxalisib and EVT801. Paxalisib is a small molecule inhibitor of the PI3K / Akt / mTOR pathway, a central regulator of growth and cell division that is dysregulated in many types of cancer. Paxalisib is being developed for several forms of brain cancer. EVT801 is a small molecule inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3), which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. EVT801 is an inhibitor of VEGFR3, a cellular receptor for VEGF. The Company’s drug candidates are designed to treat disease, such as brain cancer, renal cancer, and liver cancer.

  • Revenue in USD (TTM)14.92k
  • Net income in USD-13.54m
  • Incorporated1994
  • Employees12.00
  • Location
    Kazia Therapeutics LtdThree International Towers Level 24, 300 Barangaroo AvenueSYDNEY 2000AustraliaAUS
  • Phone+61 29472-4100
  • Fax+61 29476-0388
  • Websitehttps://www.kaziatherapeutics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
NuCana PLC (ADR)0.00-33.74m6.34m25.00--0.5312-----301.53-301.530.005.650.00----0.00-72.34-41.01-125.17-48.07------------0.0324------13.71---21.70--
Titan Pharmaceuticals Inc87.00k-4.95m6.34m4.00--1.04--72.93-6.41-6.410.11196.660.0197--1.2321,750.00-112.41-96.80-170.59-156.65-----5,694.25-406.26---415.190.00---66.97-51.1645.43---65.61--
Intelligent Bio Solutions Inc2.83m-10.03m6.42m17.00--0.5392--2.27-64.14-64.144.603.820.20412.697.77166,299.40-72.67-80.65-107.67-224.8423.33---356.09-948.541.87--0.0451--187.51367.97-28.00------
Virios Therapeutics Inc0.00-5.07m6.61m4.00---------0.2673-0.26730.00--------------------------------------56.76------
22nd Century Group Inc29.75m-62.89m6.70m64.00------0.2252-40.02-97.9317.94-3.230.405.905.47464,796.90-66.29-46.78-92.49-54.18-33.09-2.11-165.75-107.950.4284-3.674.76---20.494.03-76.94--53.60--
Integrated BioPharma, Inc.50.57m-116.00k6.72m141.00--0.355231.680.1328-0.0041-0.00411.670.62831.884.4510.76358,617.00-0.43115.51-0.569827.947.0912.09-0.22946.441.02-9.000.001---9.913.00-101.35---14.03--
Kazia Therapeutics Ltd (ADR)14.92k-13.54m6.83m12.00--0.6561--457.55-0.821-0.8210.00080.34950.0007--73.97---63.98-46.35-82.39-54.75-----90,714.45-497.17----0.1297--979.43-28.3118.19------
Actavia Life Sciences Inc0.00-406.65k6.95m1.00---------0.0005-0.00050.00-0.00280.00----0.00-805.97-158.17---------------5.63---------547.04------
Paranovus Entertainment Technology Ltd51.46m-42.62m6.97m80.00--0.6528--0.1355-7.16-7.499.891.461.1859.614.15643,209.90-91.12-23.19-119.36-27.214.9223.09-77.15-24.253.97-2,465.220.00--9.689.80-45.84---21.93--
Pulmatrix Inc11.68m-8.85m7.00m22.00--0.3683--0.5995-2.42-2.423.205.210.3517--17.84531,090.90-26.63-46.91-30.21-58.12-----75.73-238.04----0.00--20.21116.6225.03--104.29--
Viaderma Inc17.80m2.31m7.09m75.000.00030.000021.310.398516.8416.84129.62255.590.412624.691.21237,331.305.36--6.53--28.90--12.99--2.075.660.1718---29.15---40.70------
Shuttle Pharmaceuticals Holdings Inc0.00-7.35m7.26m8.00--2.63-----0.4739-0.47390.000.16420.00----0.00-96.75---119.37-------------5.280.2542-------112.71------
Trevena Inc3.14m-40.15m7.34m23.00------2.34-2.71-2.710.2107-0.79990.0904----136,478.30-115.65-55.93-148.14-66.3548.04---1,279.01-3,134.41---15.391.88--847.61-11.4324.93---24.67--
Oragenics Inc20.63k-20.26m7.35m5.00--7.12--356.20-7.98-7.980.00790.58590.0026----4,126.00-258.71-97.60-312.34-106.24-----98,214.93-36,169.75----0.0461---71.37---44.56--51.64--
Cyclerion Therapeutics Inc0.00-10.95m7.36m1.00--0.6841-----4.380.29040.003.970.00----0.00-95.95-72.70-158.12-86.96-------2,565.62----0.00---100.00--30.98------
Data as of Jun 14 2024. Currency figures normalised to Kazia Therapeutics Ltd's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.